A Pharmacokinetic Simulation Tool for Inhaled Corticosteroids
- 900 Downloads
The pharmacokinetic (PK) behavior of inhaled drugs is more complicated than that of other forms of administration. In particular, the effects of certain physiological (mucociliary clearance and differences in membrane properties in central and peripheral (C/P) areas of the lung), formulation (as it relates to drug deposition and particle dissolution rate), and patient-related factors (lung function; effects on C/P deposition ratio) affect the systemic PKs of inhaled drugs. The objectives of this project were (1) to describe a compartmental model that adequately describes the fate of inhaled corticosteroids (ICS) after administration while incorporating variability between and within subjects and (2) based upon the model, to provide a freely available tool for simulation of PK trials after ICS administration. This compartment model allows for mucociliary removal of undissolved particles from the lung, distinguishes between central and peripheral regions of the lung, and models drug entering the systemic circulation via the lung and the gastrointestinal tract. The PK simulation tool is provided as an extension package to the statistical software R (‘ICSpkTS’). It allows simulation of PK trials for hypothetical ICS and of four commercially available ICS (budesonide, flunisolide, fluticasone propionate, and triamcinolone acetonide) in a parallel study design. Simulated PK data and parameters agreed well with literature data for all four ICS. The ICSpkTS package is especially suitable to explore the effect of changes in model parameters on PK behavior and can be easily adjusted for other inhaled drugs.
KEY WORDScompartment model inhaled corticosteroids pharmacokinetics trial simulation
We would like to thank Saskia Fuhrmann, Uta Schilling, and especially Bhargava Kandala, for all their assistance with this project.
- 1.Global Initiative for Asthma. Global strategy for asthma management and prevention. http://www.ginasthma.org/uploads/users/files/GINA_Report_2011.pdf. Accessed 12 June 2012.
- 2.Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2011_Jan21.pdf. Accessed 12 June 2012.
- 5.Brutsche MH, Brutsche IC, Munawar M, Langley SJ, Masterson CM, Daley-Yates PT, et al. Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: a randomised crossover study. Lancet. 2000;356:556–61.PubMedCrossRefGoogle Scholar
- 12.R Development Core Team. R: A language and environment for statistical computing. http://www.r-project.org/. Accessed 12 June 2012.
- 17.Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Informa Healthcare; 1982. p. 419–24.Google Scholar
- 20.Moellmann HW, Hochhaus G, Tromm A, Froehlich P, Moellmann AC, Krieg M, et al. Pharmcokinetics and pharmacodynamics of budesonide pH-modified release capsules. In: Moellmann HW, May B, editors. Glucocortocoid therapy in chronic inflammatory bowel disease. Norwell: Kluwer; 1996. p. 107–20.Google Scholar
- 30.Mollmann H, Wagner M, Krishnaswami S, Dimova H, Tang Y, Falcoz C, et al. Single-dose and steady-state pharmacokinetic and pharmacodynamic evaluation of therapeutically clinically equivalent doses of inhaled fluticasone propionate and budesonide, given as Diskus or Turbohaler dry-powder inhalers to healthy subjects. J Clin Pharmacol. 2001;41:1329–38.PubMedCrossRefGoogle Scholar
- 37.Dalby C, Polanowski T, Larsson T, Borgstrom L, Edsbacker S, Harrison TW. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Respir Res. 2009;10:104.PubMedCrossRefGoogle Scholar
- 38.Argenti D, Shah B, Heald D. A study comparing the clinical pharmacokinetics, pharmacodynamics, and tolerability of triamcinolone acetonide HFA-134a metered-dose inhaler and budesonide dry-powder inhaler following inhalation administration. J Clin Pharmacol. 2000;40:516–26.PubMedCrossRefGoogle Scholar
- 47.Mortimer KJ, Harrison TW, Tang Y, Wu K, Lewis S, Sahasranaman S, et al. Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma. J Clin Pharmacol. 2006;62:412–9.Google Scholar
- 49.Son Y-J, Horng M, Copley M, McConville JT. Optimization of an in vitro dissolution test method for inhalation formulations. Dissolution Technologies. 2010;1–8:6–13.Google Scholar